Greenwich LifeSciences (GLSI) Equity Average (2019 - 2025)
Greenwich LifeSciences filings provide 7 years of Equity Average readings, the most recent being $1.8 million for Q3 2025.
- Quarterly Equity Average fell 66.62% to $1.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Sep 2025, down 66.62% year-over-year, with the annual reading at $4.6 million for FY2024, 53.63% down from the prior year.
- Equity Average hit $1.8 million in Q3 2025 for Greenwich LifeSciences, up from $1.4 million in the prior quarter.
- Across five years, Equity Average topped out at $29.5 million in Q2 2021 and bottomed at $1.4 million in Q2 2025.
- Average Equity Average over 5 years is $13.3 million, with a median of $11.2 million recorded in 2023.
- The largest annual shift saw Equity Average skyrocketed 2170.27% in 2021 before it tumbled 74.98% in 2025.
- Greenwich LifeSciences' Equity Average stood at $27.6 million in 2021, then tumbled by 48.23% to $14.3 million in 2022, then plummeted by 45.66% to $7.8 million in 2023, then crashed by 51.67% to $3.8 million in 2024, then crashed by 51.78% to $1.8 million in 2025.
- Per Business Quant, the three most recent readings for GLSI's Equity Average are $1.8 million (Q3 2025), $1.4 million (Q2 2025), and $1.9 million (Q1 2025).